Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of bone size, not density, on the stiffness of the proximal part of normal and osteoporotic human femora.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·1992
Same author

[Prospective long-term ECG study of 100 patients surviving sudden cardiac death].

Zeitschrift fur Kardiologie·1992
Same author

Prescribing NSAIDs.

Orthopaedic review·1992
Same author

Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC].

International journal of immunopharmacology·1992
Same author

Laryngospasm during transtracheal high frequency jet ventilation.

Anaesthesia·1992
Same author

No effect of dose, hepatic function, or nutritional status on 5-FU clearance following continuous (5-day), 5-FU infusion.

British journal of cancer·1992

Related Experiment Video

Updated: Jul 10, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

[Modern therapy for systemic lupus erythematosus].

R Fischer-Betz1, M Schneider

  • 1Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität, Moorenstrasse 5, 40225, Düsseldorf, Germany. Rebecca.Fischer@med.uni-duesseldorf.de

Zeitschrift Fur Rheumatologie
|November 15, 2007
PubMed
Summary

Systemic lupus erythematosus (SLE) treatment has evolved with immunosuppressants like mycophenolate mofetil and rituximab showing promise. Long-term prognosis is improved by managing comorbidities and preventing side effects with existing therapies.

Related Experiment Videos

Last Updated: Jul 10, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) treatment options have expanded despite no new drug approvals in over 40 years.
  • Evidence for many SLE therapies is limited, but individualized immunosuppressive treatment based on disease activity is widely accepted.

Purpose of the Study:

  • To provide an overview of current SLE treatment concepts.
  • To emphasize the importance of "old medications" and "simple" measures in SLE management, including long-term prognosis and comorbidity treatment.

Main Methods:

  • Review of current literature and clinical experience regarding SLE therapies.
  • Focus on established treatments and their impact on disease activity, prognosis, and adverse effects.

Main Results:

  • Mycophenolate mofetil and rituximab show significant potential for SLE treatment based on existing data.
  • Antimalarial drugs remain valuable, contributing to disease suppression, improved long-term outcomes, and management of comorbidities.

Conclusions:

  • Individualized immunosuppressive therapy adjusted to SLE activity and severity is crucial.
  • Effective SLE management requires attention to long-term prognosis, comorbidity treatment, and prevention of treatment-related adverse effects like infections and cardiovascular issues.